Baird Financial Group, Inc. Apellis Pharmaceuticals, Inc. Transaction History

Baird Financial Group, Inc.

$50.2 Billion
Q3 2024

A detailed history of Baird Financial Group, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 27,170 shares of APLS stock, worth $900,413. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,170

Previous 27,028 0.53%

Holding current value

$900,413

Previous $1.04 Million 24.42%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $4,095 - $5,843	142 Added 0.53%	27,170 $783,000
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $18,311 - $28,720	481 Added 1.81%	27,028 $1.04 Million
Q1 2024 May 14, 2024	BUY	$55.39 - $72.47 $34,895 - $45,656	630 Added 2.43%	26,547 $1.56 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $570,507 - $995,700	-15,361 Reduced 37.21%	25,917 $1.55 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $50,705 - $191,287	2,144 Added 5.48%	41,278 $1.57 Million
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $1.67 Million - $2.03 Million	-21,735 Reduced 35.71%	39,134 $3.57 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $996,653 - $1.43 Million	21,392 Added 54.19%	60,869 $4.01 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $325,726 - $459,814	7,533 Added 23.58%	39,477 $2.04 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $305,621 - $475,638	-6,828 Reduced 17.61%	31,944 $2.18 Million
Q2 2022 Aug 08, 2022	SELL	$35.07 - $59.21 $543,374 - $917,399	-15,494 Reduced 28.55%	38,772 $1.75 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $42,232 - $64,456	1,191 Added 2.24%	54,266 $2.76 Million
Q4 2021 Feb 09, 2022	BUY	$30.74 - $49.16 $687,868 - $1.1 Million	22,377 Added 72.89%	53,075 $2.51 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $17,018 - $37,853	542 Added 1.8%	30,698 $1.01 Million
Q2 2021 Aug 11, 2021	SELL	$40.9 - $64.9 $332,148 - $527,052	-8,121 Reduced 21.22%	30,156 $1.91 Million
Q1 2021 May 13, 2021	BUY	$40.8 - $57.39 $877,199 - $1.23 Million	21,500 Added 128.15%	38,277 $1.64 Million
Q4 2020 Feb 11, 2021	SELL	$30.79 - $57.2 $153,980 - $286,057	-5,001 Reduced 22.96%	16,777 $960,000
Q3 2020 Nov 12, 2020	BUY	$25.89 - $33.65 $1,941 - $2,523	75 Added 0.35%	21,778 $657,000
Q2 2020 Oct 22, 2020	SELL	$24.8 - $38.49 $63,686 - $98,842	-2,568 Reduced 10.58%	21,703 $709,000
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $99,770 - $154,845	4,023 Added 19.87%	24,271 $743,000
Q1 2020 May 14, 2020	SELL	$17.91 - $44.33 $78,356 - $193,943	-4,375 Reduced 17.77%	20,248 $542,000
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $783,643 - $1.09 Million	-35,459 Reduced 59.02%	24,623 $754,000
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $123,991 - $165,630	-5,147 Reduced 7.89%	60,082 $1.45 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $1.17 Million - $1.65 Million	65,229 New	65,229 $1.65 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.

Account

Baird Financial Group, Inc. Apellis Pharmaceuticals, Inc. Transaction History